Dr. Lewis has over thirty years’ experience in the pharmaceutical industry discovering and developing novel small molecule and biological products for Merck & Co., and for Eisai Co., Ltd. While with Eisai, he most recently led the Pharmaceutical Sciences and Technology Core Function Unit (PST). PST performed chemical, manufacturing, and controls development at 10 sites in 3 countries for Eisai’s new candidate products. Previously, Dr. Lewis helped lead pharmaceutical research at Eisai’s Andover subsidiary, which focused on advanced synthetic chemistry and innate immunity. One of these programs, the complex natural product-inspired Halaven®, was a landmark chemistry approval for the treatment of metastatic breast cancer patients. Dr. Lewis currently serves as President of the Edward P. Evans Foundation, a non-profit charitable trust dedicated to developing cures for myelodysplastic syndromes.